Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) Protein
715€ (50 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx655572
tested applications
WB, SDS-PAGE
Description
Human CEACAM5 Protein (Active) is an Active recombinant Human protein expressed in 293F cells for use in cell culture and activity assays.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) |
| Host | 293F cells |
| Assay Type | Activity: Active Biological Activity: Carcinoembryonic Antigens (CEAs) are members of the CD66 cluster of differentiation. They are glycophosphatidylinositol (GPI)-anchored intercellular molecules that are upregulated in many cancers, such as colon, breast and lung. Galectin 4 (GAL4) has been identified as an interactor of CEA, thus a binding ELISA assay was conducted to detect the interaction of recombinant human CEA and recombinant human GAL4. Briefly, CEA was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to GAL4-coated microplate wells and incubated for 2 h at 37°C. Wells were washed with PBST and incubated for 1 h with anti-CEA polyclonal antibody, then aspirated and washed 3 times. After incubation with HRP-conjugated secondary antibody, wells were aspirated and washed 3 times. TMB substrate solution was added and wells were incubated for 15-25 minutes at 37 °C. Finally, 50 µl stop solution was added to the wells and the absorbance was read at 450 nm immediately. Sequence Fragment: Lys35-Ala685 Tag: N-terminal His tag |
| Origin | Human |
| Conjugation | Unconjugated |
| Observed MW | Calculated MW: 73 kDa Observed MW (SDS-PAGE): 80 kDa |
| Expression | Recombinant |
| Purity | > 98% |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Size 3 | 200 µg |
| Size 4 | 500 µg |
| Size 5 | 1 mg |
| Form | Lyophilized |
| Tested Applications | WB, SDS-PAGE |
| Buffer | Prior to lyophilization: 10 mM PBS, pH 7.6, containing 5% Trehalose. |
| Availability | Shipped within 5-7 working days. |
| Storage | Store lyophilized form at 2-8°C for up to 1 month. For longer periods, store lyophilized or liquid at -80°C. Avoid repeated freeze–thaw cycles. |
| Dry Ice | No |
| UniProt ID | P06731 |
| Gene ID | 1048 |
| Alias | CEA,CD66eMeconium antigen 100,Carcinoembryonic antigen |
| Background | Protein CEACAM5 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Reconstitute in ddH2O to a concentration between 0.1-1.0 mg/ml. Do not vortex. Endotoxin Level: < 1.0 EU per 1 µg (LAL method) Concentration: Prior to lyophilization: 350 µg/ml |
Descripción
CEACAM5, also known as carcinoembryonic antigen (CEA), is a glycoprotein member of the immunoglobulin superfamily that plays a prominent role in cell adhesion, immune modulation, and intercellular signaling. It is highly expressed in epithelial tissues and is overexpressed in various cancers, including colorectal, pancreatic, and lung cancers, where it is used as a tumor marker for diagnosis, prognosis, and monitoring therapeutic responses. CEACAM5 mediates homophilic and heterophilic adhesion, influencing cellular aggregation, invasion, and metastasis. It interacts with other CEACAM family members and cell surface receptors to regulate signaling pathways involved in cell proliferation, migration, and immune evasion. Structurally, CEACAM5 contains multiple immunoglobulin-like domains, a glycosylphosphatidylinositol (GPI) anchor, and extensive glycosylation sites that contribute to its functional diversity. In cancer, CEACAM5 promotes tumor progression by enhancing adhesion to extracellular matrix components and modulating immune responses, such as inhibiting T-cell activation. Therapeutic strategies targeting CEACAM5, including monoclonal antibodies and vaccines, are under development to exploit its role as a biomarker and driver of tumor progression. CEACAM5 also plays roles in physiological processes like epithelial cell polarity and tissue homeostasis, reflecting its multifaceted importance.
Related Products
Human CEA (Carcinoembryonic Antigen) ELISA Kit
Ver Producto
CEACAM5 antibody
Ver Producto